SynthesisJournal of thrombosis and thrombolysis2015
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Synthesis in Journal of thrombosis and thrombolysis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.Chest · 2017Pooled it
- A Review of Recent Advances in the Anticancer Mechanisms of Activity of Novel Thiazoles and 4-Thiazolidinones/Thiazolidinediones (2021-2025).Molecules (Basel, Switzerland) · 2026Review
- A narrative literature review on the clinical utility of activated partial thromboplastin time and anti-factor Xa activity assays in cancer patients with anticoagulant therapy.Translational cancer research · 2025Review
- A Novel Integrated Strategy for Discovering Absorbable Anticoagulant Bioactive Peptides: A Case Study on Leech Protein Hydrolysates.Molecules (Basel, Switzerland) · 2025Article
- Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism.Thrombosis journal · 2025Article
- Distribution of anti-factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban.Journal of arrhythmia · 2024Article
- From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again.American journal of clinical pathology · 2022Article
- Use of direct oral anticoagulants in ICU patients. Part I - Applied pharmacology.Anaesthesiology intensive therapy · 2021Review
- Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation.Frontiers in pharmacology · 2021Article
- Direct oral anticoagulants (DOACs) and neck of femur fractures: Standardising the perioperative management and time to surgery.Journal of clinical orthopaedics and trauma · 2021Article
- An illustrated review of bleeding assessment tools and common coagulation tests.Research and practice in thrombosis and haemostasis · 2020Article
- Edoxaban affects TRAP-dependent platelet aggregation.Journal of thrombosis and thrombolysis · 2020Article
- Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7).Heart and vessels · 2020Observational
- An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants.Advances in hematology · 2020Review
- Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).Heart and vessels · 2019Observational
- Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy.Journal of thrombosis and thrombolysis · 2019Article
- Emergency Reversal of Anticoagulation.The western journal of emergency medicine · 2019Review
- Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes.Journal of stroke · 2018Article
- Italian intersociety consensus on DOAC use in internal medicine.Internal and emergency medicine · 2017Article
- Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke.Journal of thrombosis and thrombolysis · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Edoxaban, an oral direct inhibitor of factor Xa, was recently approved in the United States and Japan for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for treatment of venous thromboembolism (VTE). It is also licensed in Japan for prevention of VTE after major orthopedic surgery. Although routine laboratory monitoring of edoxaban is not required, laboratory measurement may be desirable in special circumstances. Our objective was to provide a systematic review of current evidence on laboratory measurement of the anticoagulant activity of edoxaban. PubMed and the Cochrane Library were searched for studies that reported a relationship between coagulation tests and plasma edoxaban levels. Study quality was assessed using Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). We identified 9 eligible studies. Anti-Xa activity is linear across a broad range of drug levels (R (2) > 0.95) and may be used for edoxaban quantification. The assay shows greater variability at above on-therapy drug concentrations. The PT is less sensitive to edoxaban. A normal prothrombin time may not exclude clinically relevant on-therapy drug levels. The activated partial thromboplastin time has insufficient sensitivity to edoxaban for measurement of its anticoagulant activity. Edoxaban exhibits variable effects on coagulation assays. Understanding these effects facilitates interpretation of test results in edoxaban-treated patients. More data on the relationship between drug levels, coagulation test results, and clinical outcomes in patients are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.